Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.71 |
| ▸ | KLK1 | P06870 | 1/20 | 0.71 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730422 | 0.96 | F10 (0.74) | F10KLK1 | |
| SCHEMBL6421733 | 0.92 | F10 (0.71) | F10KLK1LSS | |
| SCHEMBL6424026 | 0.91 | F10 (0.67) | F10KLK1 | |
| SCHEMBL6730994 | 0.90 | F10 (0.61) | F10KLK1 | |
| SCHEMBL6737185 | 0.89 | F10 (0.68) | F10KLK1 | |
| SCHEMBL6781543 | 0.89 | F10 (0.61) | F10KLK1 | |
| SCHEMBL6421029 | 0.89 | F10 (0.65) | F10KLK1 | |
| Hydrochloric Acid SCHEMBL6783930 | 0.88 | F10 (0.60) | F10KLK1 | |
| SCHEMBL6421003 | 0.88 | F10 (0.56) | F10KLK1 | |
| SCHEMBL6728636 | 0.88 | F10 (0.58) | F10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343530-B1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | claimed |
| EP-1528061-A1 | Heterocyclic derivatives which inhibit factor Xa | AstraZeneca AB (SE) | 2005-05-04 | — | — | EP | claimed |
| EP-1082321-B1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | claimed |
| US-20040138231-A1 | Pharmaceutical composition which comprise a solid dispersion of a hydroxypropyl-methylcellulose phthalate polymer | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | claimed |
| US-6753331-B1 | INDOL-2-YLSULPHONYL-4-(4-(HETEROCYCLE)BENZOYL)PIPERAZINE DERIVATIVES AS ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2004-06-22 | — | — | US | claimed |
| US-20040076673-A1 | Oral pharmaceutical composition containing a block copolymer | MATERIAL IMPROVEMENT, LP | 2004-04-22 | — | — | US | claimed |
| EP-1365746-A1 | PHARMACEUTICAL COMPOSITION WHICH COMPRISE A SOLID DISPERSION OF A HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE POLYMER | AstraZeneca AB (SE) | 2003-12-03 | — | — | EP | claimed |
| EP-1343530-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER | AstraZeneca AB (SE) | 2003-09-17 | — | — | EP | claimed |
| WO-2002067904-A1 | PHARMACEUTICAL COMPOSITION WHICH COMPRISE A SOLID DISPERSION OF A HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE POLYMER | ASTRAZENECA AB (SE) | 2002-09-06 | — | — | WO | claimed |
| WO-2002038184-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER | ASTRAZENECA AB (SE) | 2002-05-16 | — | — | WO | claimed |
| WO-2001017990-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA UK LIMITED (GB) | 2001-03-15 | — | — | WO | claimed |
| EP-1082321-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | claimed |
| WO-1999057113-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | claimed |
| EP-1294394-B1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1528061-A1 | Heterocyclic derivatives which inhibit factor Xa | AstraZeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | ASTRAZENECA AB | 2004-12-30 | — | — | US | disclosed |
| WO-2001017990-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA UK LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
| EP-1082321-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000078749-A1 | SULFONAMIDE DERIVATIVE AS FACTOR XA INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| WO-1999057113-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | F12, TFPI, F2 | F10 9/4885KLK1 1162/4885LSS 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.